Latest filing published 06 Mar 2024 for Alivus Life Sciences Limited, €447.4M.
Filing timeline
BuySaleGlenmark Pharmaceuticals Limited: trading record in brief
This profile gathers the share dealings of Glenmark Pharmaceuticals Limited in Alivus Life Sciences Limited. In total, 2 filings cover trades dated from 21 September 2023 to 6 March 2024.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
The record was last updated on 6 March 2024 with a transaction (€447.4M) in Alivus Life Sciences Limited. Source: insider filings from SEBI (PIT + SAST). Past trades are no guide to future returns.
Companies and markets linked to Glenmark Pharmaceuticals Limited
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 67,389,944 shares@ ₹597.993887.0% of flowEquity SharesSEBI:7a6580285e4ab87778892b1e6940df5b0906ece1
- 9,609,571 shares@ ₹615.0013.0% of flowEquity SharesSEBI:a028b009998f2b6cd0e9f0078c26b6d97e983bed
2 of 2 declarations